UBS Maintains Buy on Elevance Health, Lowers Price Target to $555
Portfolio Pulse from Benzinga Newsdesk
UBS analyst A.J. Rice maintains a Buy rating on Elevance Health but lowers the price target from $605 to $555.

October 18, 2024 | 2:12 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
UBS analyst A.J. Rice maintains a Buy rating on Elevance Health but lowers the price target from $605 to $555.
The Buy rating suggests continued confidence in Elevance Health's performance, but the lowered price target indicates some caution about future growth or market conditions. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100